Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 102, Issue 4, 2008, Pages 338-345

  Hamel, Mary J ^a,d   Poe, Amanda ^a,b   Bloland, Peter ^a   McCollum, Andrea ^a,b,c   Zhou, Zhiyong ^a,b   Shi, Ya Ping ^a   Ouma, Peter ^a,d   Otieno, Kephas ^a,d   Vulule, John ^d   Escalante, Ananias ^a,e   Udhayakumar, Venkatachalam ^a   Slutsker, Laurence ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^c EMORY UNIVERSITY   (United States)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e ARIZONA STATE UNIVERSITY   (United States)

Author keywords

DHFR; Drug resistance; Malaria; Mutation; Plasmodium falciparum; Sulfadoxine pyrimethamine

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; FANSIDAR; FOLIC ACID ANTAGONIST; INSECTICIDE; ISOLEUCINE; LEUCINE; MULTIVITAMIN; QUININE;

ADOLESCENT; ADULT; AGED; ARTICLE; BED NET; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALE; MICROSCOPY; MUTATIONAL ANALYSIS; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROTOZOAL GENETICS; THERAPY RESISTANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIMALARIALS; CD4 LYMPHOCYTE COUNT; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

PLASMODIUM FALCIPARUM;

EID: 40249118197     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2008.01.018     Document Type: Article

References (26)

1. Alker A.P., Mwapasa V., Purfield A., Rogerson S.J., Molyneux M.E., Kamwendo D.D., Tadesse E., Chaluluka E., and Meshnick S.R. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob. Agents Chemother. 49 (2005) 3919-3921
2. Bates S.J., Winstanley P.A., Watkins W.M., Alloueche A., Bwika J., Happi T.C., Kremsner P.G., Kublin J.G., Premji Z., and Sibley C.H. Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites. J. Infect. Dis. 190 (2004) 1783-1792
3. Bloland P.B., Boriga D.A., Ruebush T.K., McCormick J.B., Roberts J.M., Oloo A.J., Hawley W., Lal A., Nahlen B., and Campbell C.C. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission ii. Descriptive epidemiology of malaria infection and disease among children. Am. J. Trop. Med. Hyg. 60 (1999) 641-648
4. Buve A., Carael M., Hayes R.J., Auvert B., Ferry B., Robinson N.J., Anagonou S., Kanhonou L., Laourou M., Abega S., Akam E., Zekeng L., Chege J., Kahindo M., Rutenberg N., Kaona F., Musonda R., Sukwa T., Morison L., Weiss H.A., and Laga M. Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. Aids 15 Suppl. 4 (2001) S5-S14
5. Bwijo B., Kaneko A., Takechi M., Zungu I.L., Moriyama Y., Lum J.K., Tsukahara T., Mita T., Takahashi N., Bergqvist Y., Bjorkman A., and Kobayakawa T. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop. 85 (2003) 363-373
6. Chandramohan D., Owusu-Agyei S., Carneiro I., Awine T., Amponsa-Achiano K., Mensah N., Jaffar S., Baiden R., Hodgson A., Binka F., and Greenwood B. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. Br. Med. J. 331 (2005) 727-733
7. Cisse B., Sokhna C., Boulanger D., Milet J., Bâ E.H., Richardson K., Hallett R., Sutherland C., Simondon K., Simondon F., Alexander N., Gaye O., Targett G., Lines J., Greenwood B., and Trape J.F. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367 (2006) 659-667
8. Diourte Y., Djimde A., Doumbo O.K., Sagara I., Coulibaly Y., Dicko A., Diallo M., Diakite M., Cortese J.F., and Plowe C.V. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am. J. Trop. Med. Hyg. 60 (1999) 475-478
9. Githeko A.K., Service M.W., Mbogo C.M., Atieli F.K., and Juma F.O. Plasmodium falciparum sporozoite and entomological inoculation rates at the Ahero rice irrigation scheme and the Miwani sugar-belt in western Kenya. Ann. Trop. Med. Parasitol. 87 (1993) 379-391
10. Hastings M.D., Bates S.J., Blackstone E.A., Monks S.M., Mutabingwa T.K., and Sibley C.H. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans. R. Soc. Trop. Med. Hyg. 96 (2002) 674-676
11. Jelinek T., Kilian A.H., Kabagambe G., and von Sonnenburg F. Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes. Am. J. Trop. Med. Hyg. 61 (1999) 463-466
12. Krudsood S., Imwong M., Wilairatana P., Pukrittayakamee S., Nonprasert A., Snounou G., White N.J., and Looareesuwan S. Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Trans. R. Soc. Trop. Med. Hyg. 99 (2005) 142-149
13. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., and Plowe C.V. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185 (2002) 380-388
14. Macete E., Aide P., Aponte J.J., Sanz S., Mandomando I., Espasa M., Sigauque B., Dobano C., Mabunda S., DgeDge M., Alonso P., and Menendez C. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J. Infect. Dis. 194 (2006) 276-285
15. Mberu E.K., Nzila A.M., Nduati E., Ross A., Monks S.M., Kokwaro G.O., Watkins W.M., and Hopkins Sibley C. Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance. Exp. Parasitol. 101 (2002) 90-96
16. McCollum A.M., Poe A.C., Hamel M., Huber C., Zhou Z., Shi Y.P., Ouma P., Vulule J., Bloland P., Slutsker L., Barnwell J.W., Udhayakumar V., and Escalante A.A. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J. Infect. Dis. 194 (2006) 189-197
17. Mutabingwa T., Nzila A., Mberu E., Nduati E., Winstanley P., Hills E., and Watkins W. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358 (2001) 1218-1223
18. Nzila A.M., Mberu E.K., Sulo J., Dayo H., Winstanley P.A., Sibley C.H., and Watkins W.M. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44 (2000) 991-996
19. Nzila-Mounda A., Mberu E.K., Sibley C.H., Plowe C.V., Winstanley P.A., and Watkins W.M. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42 (1998) 164-169
20. Obonyo C.O., Ochieng F., Taylor W.R., Ochola S.A., Mugitu K., Olliaro P., ter Kuile F., and Oloo A.J. Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 585-591
21. Plowe C.V., Cortese J.F., Djimde A., Nwanyanwu O.C., Watkins W.M., Winstanley P.A., Estrada-Franco J.G., Mollinedo R.E., Avila J.C., Cespedes J.L., Carter D., and Doumbo O.K. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 176 (1997) 1590-1596
22. Schellenberg D., Menendez C., Kahigwa E., Aponte J., Vidal J., Tanner M., Mshinda H., and Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357 (2001) 1471-1477
23. Shah S.N., Smith E.E., Obonyo C.O., Kain K.C., Bloland P.B., Slutsker L., and Hamel M.J. HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J. Infect. Dis. 194 (2006) 1519-1528
24. Sibley C.H., Hyde J.E., Sims P.F., Plowe C.V., Kublin J.G., Mberu E.K., Cowman A.F., Winstanley P.A., Watkins W.M., and Nzila A.M. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?. Trends Parasitol. 17 (2001) 582-588
25. Staedke S.G., Sendagire H., Lamola S., Kamya M.R., Dorsey G., and Rosenthal P.J. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health 9 (2004) 624-629
26. WHO, 2006. WHO Facts on ACTS (Artemisinin-Based Combination Therapies), January 2006 Update. World Health Organization, Geneva. http://www.who.int/malaria/cmc_upload/0/000/015/364/RBMInfosheet_9.pdf [accessed 3 December 2007].